COL3A1 and breast carcinoma: Another study has shown that when Pirfenidone, an anti-fibrotic drug, was applied to breast cancer to investigate its possible role on tumor microenvironment normalization, the level of COL3A1 was down-regulated, thereby inhibiting the TGFβ signaling pathway.